World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
112
Citations
56178
World Ranking
5088
National Ranking
200

Overview

Kim Papp is affiliated with Probity Medical Research in Canada and has contributed extensively to the fields of medicine, immunology, and dermatology. Their research productivity spans multiple areas such as immunology, rheumatology, pediatrics, and allergy, with a focus on skin diseases and autoimmune conditions.

The primary research domains include:

  • Medicine
  • Immunology and Microbiology

Within these domains, subfields of study highlight:

  • Immunology
  • Dermatology
  • Rheumatology
  • Immunology and Allergy
  • Pediatrics, Perinatology and Child Health

Papp's research topics cover a broad spectrum of dermatological and immunological issues, with an emphasis on clinical treatment and pharmaceutical research. The main subjects of their work include:

  • Psoriasis: Treatment and Pathogenesis
  • Dermatology and Skin Diseases
  • Pharmaceutical Studies and Practices
  • Autoimmune Bullous Skin Diseases
  • Health Systems, Economic Evaluations, Quality of Life
  • Asthma and Respiratory Diseases
  • Allergic Rhinitis and Sensitization

Their frequent collaborators indicate active engagement in multidisciplinary research. Notable co-authors are:

  • Melinda Gooderham
  • Andrew Blauvelt
  • Mark Lebwohl
  • Leon Kircik
  • Linda Stein Gold

Papp has published in a number of dermatology and medical journals. The most recurrent venues for their work include:

  • Journal of the American Academy of Dermatology
  • SKIN The Journal of Cutaneous Medicine
  • Dermatology and Therapy
  • British Journal of Dermatology
  • Journal of the European Academy of Dermatology and Venereology

Recent publications by Kim Papp illustrate the focus on clinical trials and therapeutic interventions for skin diseases. Selected papers include:

  • "Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials," 2021, The Lancet
  • "Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial," 2022, Journal of the American Academy of Dermatology
  • "Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial," 2021, The Lancet
  • "Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies," 2021, Journal of the American Academy of Dermatology
  • "Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program for Evaluation of TYK2 inhibitor psoriasis second trial," 2022, Journal of the American Academy of Dermatology

Best Publications

  • Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

    Craig L Leonardi;Alexa B Kimball;Kim A Papp;Newman Yeilding

  • Secukinumab in plaque psoriasis--results of two phase 3 trials.

    Richard G. Langley;Boni E. Elewski;Mark Lebwohl;Kristian Reich

  • Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

    Andrew Blauvelt;Marjolein de Bruin-Weller;Melinda Gooderham;Jennifer C. Cather

  • Infliximab induction and maintenance therapy for moderate-to-severe psoriasis : a phase III, multicentre, double-blind trial

    Kristian Reich;Frank O Nestle;Kim Papp;Jean-Paul Ortonne

  • Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial

    Stephen Tyring;Alice Gottlieb;Kim Papp;Ken Gordon

  • Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis

    Kim A Papp;Craig Leonardi;Alan Menter;Jean-Paul Ortonne

  • Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

    Alan Menter;Stephen K. Tyring;Kenneth Gordon;Alexa B. Kimball

  • Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

    Mark Lebwohl;Bruce Strober;Alan Menter;Kenneth Gordon

  • Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

    Andrew Blauvelt;Kim A. Papp;Christopher E.M. Griffiths;Bruce Randazzo;Bruce Randazzo

  • A global phase III randomized controlled trial of etanercept in psoriasis : safety, efficacy, and effect of dose reduction

    Kim A. Papp;S. Tyring;M. Lahfa;J. Prinz

  • Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

    Christopher E M Griffiths;Kristian Reich;Mark Lebwohl;Peter van de Kerkhof

  • Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).

    Jean-Hilaire Saurat;G. Stingl;L. Dubertret;K. Papp

  • Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

    Kenneth B Gordon;Jean-Frederic Colombel;Dana S Hardin

  • Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study.

    Arthur Kavanaugh;Iain McInnes;Philip Mease;Gerald G. Krueger

  • Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.

    Alexa B Kimball;Martin M Okun;David A Williams;Alice B Gottlieb

  • Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial.

    Diamant Thaçi;Eric L Simpson;Lisa A Beck;Thomas Bieber

  • Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

    Kim Papp;Kristian Reich;Craig L. Leonardi;Leon Kircik

  • A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis

    Alan Menter;Steven R. Feldman;Gerald D. Weinstein;Kim Papp

  • Increase in TNF-α and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a)

    Michelle A. Lowes;Francesca Chamian;Maria Veronica Abello;Judilyn Fuentes-Duculan

  • Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials

    Kenneth B Gordon;Bruce Strober;Mark Lebwohl;Matthias Augustin

Frequent Co-Authors

Richard G. Langley
Richard G. Langley Dalhousie University
Kenneth B. Gordon
Kenneth B. Gordon Medical College of Wisconsin
Mark Lebwohl
Mark Lebwohl Icahn School of Medicine at Mount Sinai
Andrew Blauvelt
Andrew Blauvelt Veterans Health Administration
Kristian Reich
Kristian Reich University of Göttingen
Alice B. Gottlieb
Alice B. Gottlieb Icahn School of Medicine at Mount Sinai
Craig L. Leonardi
Craig L. Leonardi Saint Louis University
Christopher E.M. Griffiths
Christopher E.M. Griffiths University of Manchester
Carle Paul
Carle Paul Federal University of Toulouse Midi-Pyrénées
Diamant Thaçi
Diamant Thaçi University of Lübeck

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you are interested in medicine but want alternative education pathways, many accredited online programs offer flexible options. For nurses seeking advancement, some rn to bsn online no clinicals programs eliminate the need for on-site clinicals, making it more convenient for working professionals to earn their degree.

Those aiming for leadership or advanced practice roles might consider pursuing graduate studies. There are now shortest online dnp program options, which allow qualified nurses to obtain a Doctor of Nursing Practice quickly. Some institutions even offer easiest dnp programs that emphasize practical coursework and manageable requirements, appealing to those balancing work and study.

For those looking to enter the healthcare field faster, fast track lpn programs online enable students to become Licensed Practical Nurses in a shorter period. These pathways support a diverse range of career goals—from bedside care to advanced practice—while taking advantage of flexible, accessible online learning.

Best Scientists Citing Kim Papp

Trending Scientists

Recently Published Articles